“In this study, we demonstrated that three mutations, the RSYLTPGD246-253N, L452Q and F490S mutations, respectively confer resistance to the vaccine-induced antiviral immunity. Additionally, the T76I and L452Q mutations contribute to enhanced viral infectivity. Our data suggest that there are at least two virological features on the Lambda variant: increasing viral infectivity (by the T76I and L452Q mutations) and exhibiting resistance to antiviral immunity (by the RSYLTPGD246-253N, L452Q and F490S mutations).”
PHE England have recently published new reports on the SARS-COV-2 variants circulating in Britain: Alpha, Beta, Gamma, Zeta, Eta, B.1.1.318, Theta, Kappa, B.1.617.3, AV.1, C.36.3, Lambda, C.37
Variants under surveillance
Secondary attack rates
SARS-CoV-2 Immunity and Reinfection Evaluation (the SIREN study) cohort monitoring
Part 2: Delta (B.1.617.2) surveillance
Surveillance through genomic data
Delta with K417N (Delta-AY.1)
Data on individual variants
Lambda (C.37, VUI-21JUN-01)
“We also observed that the spike protein of the Lambda variant presented increased infectivity when compared with the spike protein of the Alpha and Gamma variants, both of them with reported increased infectivity and transmissibility. Together, our data show for the first time that mutations present in the spike protein of the Lambda variant confer escape to neutralizing antibodies and increased infectivity.”
“The evidence presented here reinforces the idea that massive vaccination campaigns in countries with high SARS-CoV-2 circulation rates must be accompanied by strict genomic surveillance aimed to rapidly identify new viral isolates carrying spike mutations as well as studies aimed to analyze the impact of these mutations in immune escape and vaccines breakthrough.”
We report the emergence of a novel lineage of SARS-CoV-2 in South America, termed C.37. It presents seven nonsynonymous mutations in the Spike gene (Δ247-253, G75V, T76I, L452Q, F490S, T859N) and a deletion in the ORF1a gene (Δ3675-3677) also found in variants of concern (VOCs) Alpha, Beta, and Gamma. Initially reported in Lima, Peru, in late December 2020, it now accounts for 97% of Peruvian public genomes in April 2021. It is expanding in Chile and Argentina, and there is evidence of onward transmission in Colombia, Ecuador, Mexico, the USA, Germany, and Israel. On June 15, 2021, the World Health Organization designated C.37 as Variant of Interest (VOI) Lambda.
The World Health Organization (WHO) said Wednesday that the coronavirus variant of COVID-19, commonly known as C.37, has been named Lambda. Lambda has been identified in 29 countries, most notably in South America where it is believed to have originated.
First identified in Peru, the Lambda lineage was classified as a global Variant of Interest on Monday due to an “elevated prevalence” in South America, the WHO said in its weekly update.
Lambda has been rampant in Peru where 81 percent of COVID-19 cases since April 2021 were associated with this variant, authorities reported.
In Chile, it was detected in 32 percent of all submitted sequences in the last 60 days, and only outclassed by the Gamma (P.1) variant which was first identified in Brazil. Other countries such as Argentina and Ecuador have also reported elevated prevalence of the new variant.
The WHO reported that the Lambda lineage carries mutations that might increase transmissibility or strengthen the virus’s resistance to antibodies.
However, evidence is too limited for the moment, the Geneva-based organization said, and more studies are required to understand better the Lambda variant.
** Our opinion: At the moment, the Sars-CoV-2 infection numbers in South America seem to be declining after peaking in June 2021. The Delta variant seems to be more of a threat internationally when you compare Latin America infection figures with the UK figures for example **
Lineage prevalence in Peru: